A significant clinical challenge is relative resistance to erythropoietin, which leads to use of successively higher erythropoietin doses, failure to achieve target hemoglobin levels, and increased risk of adverse outcomes.
"end-of-dose failure" of a long acting opioid [ 35, 36].
BTCP may be classified into three subtypes, ie, non-incident pain, incident pain, and end-of-dose failure.
Indeed, when severe sufferers were examined separately, both satisfaction measures related to end of dose failure favored desloratadine outcomes.
Our results confirm the need to administer booster doses; failure the booster is the principal determinant for the outbreak onset.
Two-thirds of patients (61.7%) could identify precipitants (movement 20.4%, end-of-dose failure 13.2%), and pain was unpredictable in most cases (78.2%).
This confirms that OROS® hydromorphone provides consistent pain relief over 24 hours and that there is little end-of-dose failure pain.
Point estimates again suggest a consistent pattern favoring desloratadine patient satisfaction, with statistically significant results reported for sum of adverse events, end of dose failure – nighttime awakenings, end of dose failure – morning symptoms, and overall satisfaction with current Rx (p < 0.05).
Respondents were also asked to indicate how frequently their allergy symptoms prevented them from sleeping through the night, a measure we report as "end of dose failure – nighttime awakenings".
Respondents were further asked to indicate how troubled they were by their allergy symptoms when they get out of bed in the morning, a measure we report as "end of dose failure – morning symptoms".
